ReviewClinical and experimental immunology2025
Neuro-Behçet's disease: an update of clinical diagnosis, biomarkers, and immunopathogenesis.
Review in Clinical and experimental immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Mapping Neuro Behcet's Disease Across North Africa: a Systematic Review and Meta Analysis.Clinical reviews in allergy & immunology · 2026Pooled it
- MRI features of parenchymal neuro-Behçet's disease: a systematic review and meta-analysis.Frontiers in neurology · 2026Pooled it
- Glymphatic dysfunction as a potential mechanistic link to cognitive ımpairment in Behçet's disease: a hypothesis.Rheumatology international · 2026Article
- Psychosocial and Functional Determinants of Central Sensitisation in Patients with Behçet's Disease: A Cross-Sectional Study.Mediterranean journal of rheumatology · 2026Article
- Targeting the BlyS/APRIL axis in neuro-Behçet disease: a rationale for telitacicept as a steroid-sparing strategy.Annals of medicine and surgery (2012) · 2026Article
- Correlation analysis of cytokine levels and peripheral blood T lymphocyte subsets in systemic vascular inflammatory disease.Journal of medical biochemistry · 2026Article
- Elevated Peripheral CD161ACR open rheumatology · 2026Article
- Recurrent Stroke Presentation in Neuro-Behcet Disease: Clinical Insights from a Case Report.Cureus · 2026Article
- Acute neurological Behçet's disease complicated by a syndrome of inappropriate secretion of antidiuretic hormone.BMJ case reports · 2026Article
- Two cases of probable Neuro-Behçet syndrome treated with autologous HSCT.Frontiers in immunology · 2026Article
- Clinical Use of Interleukin-6 Blockade in Neuroimmunological Disorders.Noro psikiyatri arsivi · 2026Review
- Neurofilament Light Chain as a Potential Serum-Based Biomarker for Monitoring Disease Activity in Neuro-Behçet's Disease.Noro psikiyatri arsivi · 2026Article
- CD39 in the pathogenesis of neuro-Behçet disease: is it an immune regulator marker?Frontiers in immunology · 2026Review
- Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Clinical Characteristics, MRI Findings, Disease Progression, and Management of Neuro-Behçet's Disease: A Retrospective Study in Lebanon.Journal of clinical medicine · 2025Article
- Clinical characteristics and treatment strategies for A20 haploinsufficiency in Japan: a national epidemiological survey.Frontiers in immunology · 2025Article
- Neuro-Behçet's disease: a pictorial essay.Radiologia brasileiraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Neuro-Behçet's disease (NBD) is a more severe but rare symptom of Behçet's disease, which is mainly divided into parenchymal NBD (p-NBD) involving brain stem, spinal cord, and cerebral cortex. Non-p-NBD manifests as intracranial aneurysm, cerebral venous thrombosis, peripheral nervous system injuries, and mixed parenchymal and non-parenchymal disease. p-NBD is pathologically characterized by perivasculitis presenting with cerebrospinal fluid (CSF) pleocytosis, elevated total protein, and central nervous system (CNS) infiltration of macrophages and neutrophils, which are subdivided into acute and chronic progressive stages according to relapsing-remitting courses and responses to steroids. The diagnosis of NBD depends heavily on clinical features and magnetic resonance imaging (MRI) findings. The lack of laboratory biomarkers has hindered standard diagnostics. CSF interleukin (IL)-6 is the most investigated dimension of NBD and correlates with NBD activity, therapeutic responses, and prognosis. Further investigations have focused on inflammatory biomarkers that reflect the activation of innate and adaptive immune responses. Higher levels of CSF migration inhibitory factor and immunosuppressive acidic protein indicated the activation of macrophages in the CNS; increased IL-17, IL-10, T-bet/GATA-3, and retinoic acid related orphan receptor (ROR)-γt/Foxp3 ratios, marking the disrupted scale of the Th1/Th2 and Th17/Treg axis; and elevated B-cell activating factor of the TNF family (BAFF) and IgA/IgM intrathecal synthesis, suggesting that B cells play a dominant role in NBD. CNS destruction and degeneration as a consequence of neuroinflammatory cascades were confirmed by elevated CSF levels of NFL, β2MG, and MBP. Autoantibodies, including anti-STIP-1, anti-Mtch1, anti-B-Crystallin, and anti-m-Hsp65, provide substantial evidence for autoimmune essence and underlying microbiological infections in NBD immunopathogenesis. We summarized opinions on the clinical diagnosis, biomarkers, and pathological findings of NBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.